Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultrarare disease therapies, has announced the grant of 22,405 restricted stock units to six newly hired non-executive officers. The grants were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on October 16, 2024.
These stock units are designed as an employment inducement, aligning with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans four years, with 25% of the shares vesting annually on the grant date anniversary, contingent on continuous employment with Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), un'azienda biofarmaceutica specializzata nelle terapie per malattie rare e ultrarare, ha annunciato la concessione di 22.405 unità azionarie limitate a sei nuovi dirigenti non esecutivi assunti. Le concessioni sono state approvate dal comitato per la remunerazione della società e sono state emesse nell'ambito del Piano di Induzione all'Occupazione di Ultragenyx il 16 ottobre 2024.
Queste unità azionarie sono concepite come un incentivo all'occupazione, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Il piano di maturazione si estende per quattro anni, con il 25% delle azioni che matura annualmente nell'anniversario della data di concessione, con l'obbligo di un impiego continuo presso Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una empresa biofarmacéutica especializada en terapias para enfermedades raras y ultra raras, ha anunciado la concesión de 22,405 unidades de acciones restringidas a seis nuevos oficiales no ejecutivos contratados. Las concesiones fueron aprobadas por el comité de compensación de la empresa y emitidas bajo el Plan de Inducción al Empleo de Ultragenyx el 16 de octubre de 2024.
Estas unidades de acciones están diseñadas como un incentivo laboral, en alineación con la Regla de Listado de Nasdaq 5635(c)(4). El calendario de adquisición se extiende a lo largo de cuatro años, con el 25% de las acciones adquiriendo derechos anualmente en el aniversario de la fecha de concesión, condicionado a la continuidad del empleo en Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), 희귀 및 초희귀 질병 치료를 전문으로 하는 바이오 제약 회사는 여섯 명의 새로 채용된 비상임 임원에게 22,405 주식 제한 단위를 부여했다고 발표했습니다. 이 부여는 회사의 보상 위원회에 의해 승인되었으며 2024년 10월 16일 Ultragenyx 고용 유인 계획에 따라 발행되었습니다.
이러한 주식 단위는 고용 유인으로 설계되었으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다. 베스팅 일정은 4년에 걸쳐 있으며, 부여된 날의 기념일에 매년 25%의 주식이 베스팅됩니다. 이는 Ultragenyx에 지속적으로 고용되어 있어야 합니다.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), une entreprise biopharmaceutique spécialisée dans les thérapies pour les maladies rares et ultrarare, a annoncé l'octroi de 22 405 unités d'actions restreintes à six nouveaux dirigeants non exécutifs embauchés. Les attributions ont été approuvées par le comité de rémunération de l'entreprise et émises dans le cadre du Plan d'Incitation à l'Emploi d'Ultragenyx le 16 octobre 2024.
Ces unités d'actions sont conçues comme un incitatif à l'emploi, conformément à la Règle de Cotation Nasdaq 5635(c)(4). Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % des actions acquérant des droits chaque année à l'anniversaire de la date d'octroi, sous réserve d'un emploi continu chez Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene und ultrarare Krankheiten spezialisiert hat, hat die Gewährung von 22.405 eingeschränkten Aktieneinheiten an sechs neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die Gewährungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und im Rahmen des Ultragenyx Employment Inducement Plans am 16. Oktober 2024 ausgegeben.
Diese Aktieneinheiten sind als Anreiz für die Beschäftigung konzipiert und entsprechen der Nasdaq-Listingregel 5635(c)(4). Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25 % der Aktien jährlich am Jahrestag des Gewährungsdatums übertragen werden, vorausgesetzt, dass eine kontinuierliche Beschäftigung bei Ultragenyx besteht.
- Ultragenyx is attracting new talent by offering competitive stock-based compensation
- The company is expanding its workforce with six new non-executive officers
- The stock grant may lead to potential dilution for existing shareholders
NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 22,405 restricted stock units of the company’s common stock to six newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees?
What is the vesting schedule for the restricted stock units granted by Ultragenyx (RARE)?
When were the restricted stock units granted by Ultragenyx (RARE)?
Under which plan were the Ultragenyx (RARE) stock grants issued?
